Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method

ABSTRACT

A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose. The delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophobic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules. Methods for forming the so-described biphasic controlled release delivery system and using such biphasic controlled release delivery system for treating diabetes are also provided.

REFERENCE TO OTHER APPLICATIONS

This is divisional of U.S. application Ser. No. 09/398,107 filed Sep.16, 1999, U.S. Pat. No. 6,475,521 B1, which is a continuation-in-part ofU.S. application Ser. No. 09/044,446 filed Mar. 19, 1998, now abandoned.

FIELD OF THE INVENTION

The present invention relates to a new dosage form for highly watersoluble medicaments, such as the antidiabetic metformin, which providesfor extended release of the drug and also for prolonged gastricresidence, so that a dosing regimen of at least one gram metformin oncedaily, may be achieved while providing effective control of plasmaglucose, and to a method for treating diabetes employing such dosageform.

BACKGROUND OF THE INVENTION

Metformin is an antihyperglycemic agent of the biguanide class used inthe treatment of non-insulin dependent diabetes mellitus (NIDDM). It isusually marketed in the form of its hydrochloride salt as Glucophage®(TM-BMS).

Metformin hydrochloride has intrinsically poor permeability in the lowerportion of the gastrointestinal tract leading to absorption almostexclusively in the upper part of the gastrointestinal tract. Its oralbioavailability is in the range of 40 to 60% decreasing with increasingdosage which suggests some kind of saturable absorption process, orpermeability/transit time limited absorption. It also has a very highwater solubility (>300 mg/ml at 25° C.). This can lead to difficulty inproviding a slow release rate from a formulation and problems incontrolling the initial burst of drug from such a formulation. These twodifficulties are further compounded by the high unit dose, 500 mg pertablet, usually required for metformin hydrochloride (1997-PDR).

Drugs that have absorption limited to the upper gastrointestinal tractcoupled with poor absorption in the distal small intestine, largeintestine and colon are usually regarded as inappropriate candidates forformulation into oral controlled delivery systems. This limitation onabsorption (for example, in the upper gastrointestinal tract) isreferred to as the “absorption window”.

The gastrointestinal tract functions to propel ingested material fromthe stomach (where digestion takes place) into the small intestine(where absorption principally occurs) and on to the large intestine(where water is absorbed/secreted as part of body fluid regulationprocesses). Residence time for non-digestible materials in the stomachdepends on whether one is dealing with a fed or a fasted subject.Typical gastric emptying times for particulate material (greater than afew millimeters in diameter) varies from a few tens of minutes in thefasted state to a few hours in the fed state. Transit times through thesmall intestine are consistently of the order of 3 to 4 hours.

Oral controlled release delivery systems function by releasing theirpayload of drug over an extended period of time followingadministration. Thus, controlled release dosage forms may only spend arelatively short period in the regions of the gastrointestinal tractwhere good absorption of certain drugs can occur. The dosage form willpass on to regions of the intestine where absorption of certain drugs ispoor or non-existent, still releasing its contained drug albeit with asignificant percentage of its payload still to be delivered. Drug whenreleased from the dosage form in the circumstances described will not beabsorbed. Thus, administration of a drug subject to a window ofabsorption in a conventional controlled release delivery system can leadto subtherapeutic blood levels and ineffective treatment of the diseasestate for which the drug was intended.

Drugs with very high solubility in water (for example, greater than 100mg/ml) can be difficult to formulate into a controlled release oraldosage form. Solubility is a driving force for a drug substance todissolve in water; the greater the solubility the greater the rate ofdissolution when all other factors are maintained constant.

In a controlled release dosage form, the formulator tries to reduce therate of dissolution by, for example, embedding the drug in a polymericmatrix or surrounding it with a polymeric barrier membrane through whichdrug must diffuse to be released for absorption. To reduce the rate ofrelease of drug from the dosage form to an appropriate level consistentwith the blood level profile desired for a drug possessing very highwater solubility, very large amounts of polymer would be required forthe matrix or barrier membrane. If the total daily dose of drug to bedelivered is of the order of only a few milligrams this may be feasible,but many drugs having the solubility properties described require totaldaily doses of the order of many hundreds of milligrams. Whilst it ispossible to create oral controlled release dosage forms for suchproducts by use of large amounts of polymer, an unacceptably largedosage form may result.

A further problem with highly water soluble drugs formulated into acontrolled release dosage form is that a significant and variable“burst” of drug can occur from these systems. The burst of highly watersoluble drug is the initial rapid release of drug that occurs from oralcontrolled release dosage forms when first contacting fluid, such asgastric fluids, prior to release controlling mechanisms of the dosageform establishing themselves and a stable release rate being provided.Hydration of any polymer matrix used to formulate the dosage form is apre-requirement of establishing a stable release rate. Thus, a readilyhydrating polymer is required to establish the desired stable releaserate. However, if the polymer used is slow to hydrate, then anundesireable variable burst can occur.

Studies by Vidon et al (1) strongly suggest that there is permeabilitylimited absorption of metformin. Perfusing drug into the jejunum via anintubation technique showed a 2.5 fold greater area under the plasmaconcentration-time profile (a measure of the quantity of drug absorbed)compared with similar introduction of drug into the ileum. Drug was notdetectable in plasma when drug was perfused into the colon. Drug willtransit down the small intestine following dissolution from an ingesteddosage form and, if absorption rate is slow, it is possible that drugcan reach regions of poor permeability before absorption of a given doseis complete. In such a case, increasing the given dose may be predictedto result in a reduction in the percentage of administered doseabsorbed.

Improvements in the therapeutic regimes employing metformin might beachieved by a dosage form that allows a reduction in dosing frequency,providing patient convenience that would probably improve compliance.Conventional extended release formulations have been demonstrated toinvariably compromise the availability of metformin (2), (2A), and (2B).This is probably because the dosage form carries a significantproportion of the drug content remaining to be released, as the dosageform is carried to regions of the gastrointestinal tract with very poorpermeability to the drug. To reduce dosing frequency, the rate ofrelease from the dosage form must be such as to extend effective plasmalevels, but the potential for effective delivery at this rate iscompromised by the combined influences of the significant reduction inpermeability to the drug in passing from the proximal small intestinedown to the colon and the limited residence time in the regions of thegastrointestinal tract where the drug is well absorbed. That transittime down the “useful” region of the gastrointestinal tract is onlylikely to be of the order of a few hours.

Maintained or even improved bioavailability from an extended releasedosage form that releases metformin at a rate likely to provide thedesired plasma levels of drug for an extended time period might,however, be possible from a dosage form that has extended residence timein the upper gastrointestinal tract, resisting mechanisms that promotenormal transit time for solid materials. That this principle might workin practice was demonstrated in an in-house study where metformin wasco-administered with propantheline, an agent that reducesgastrointestinal motility. Compared with giving metformin alone, thecombination provided an increased AUC, a delayed tmax and an extendedtime period over which therapeutically beneficial plasma levels of drugwere maintained.

Giving a drug such as metformin for the treatment of diabetes with afurther drug, such as propantheline, not used for the treatment ofdiabetes and where the sole intent of using the second agent is toachieve extended residence time in the upper GI tract, has manydisadvantages although it is likely to allow effective extended deliveryof metformin to an optimal absorption site. The co-administered drug mayhave other undesirable pharmacological effects or side effectsdeleterious to the patients well being and detract from the improvedquality of life offered by the treatment for their diabetes.Furthermore, it may be difficult or impossible to appropriatelyco-formulate the two agents due to chemical compatibility issues orsolubility differences, the latter preventing the required release rateof agent influencing residence time in the upper GI tract. Thus, thepatient could be required to take separate, multiple medications toachieve the desired effect. The timing of taking the two medicationswould be critical to effective delivery of the drug with the limitedwindow of absorption and many patients may thus fail to take theirmedication correctly resulting in ineffective treatment of theirdiabetes.

Prior Art Gastro-Retentive Systems

It would be desirable to provide a dosage form that inherently has theproperty of extended gastric residence, possessing some resistance tothe pattern of waves of motility present in the gastrointestinal tractthat serve to propel material through it. There have been many attemptsto provide for this, with varying degrees of success.

Possible approaches described in prior art include:

(1) Floating or buoyant systems:

These are designed to have a low density and thus should float ongastric contents after administration until the system eitherdisintegrates (and presumably the resultant particles empty from thestomach) or the device absorbs fluid to the point where its density issuch that it loses buoyancy and can pass more easily from the stomachwith a wave of motility responsible for gastric emptying.

(2) Bioadhesive systems:

These are designed to imbibe fluid following administration such thatthe outer layer becomes a viscous, tacky material that adheres to thegastric mucosa/mucus layer. This should encourage gastric retentionuntil the adhesive forces are weakened for example by continuinghydration of the outer layer of the device or by the persistentapplication of shear.

(3) Swelling and expanding systems:

These are designed to be sufficiently small on administration so as notto make ingestion of the dosage form difficult (for example, less thanapproximately 23 mm long and less than 11 mm wide for an oval orcapsule-shaped tablet). On ingestion they rapidly swell or unfold to asize that precludes passage through the pylorus until after drug releasehas progressed to a required degree. Gradual erosion of the system orits breakdown into smaller particles enables it to leave the stomach.

Re: (1) Buoyant/floating Systems

Buoyant systems designed to float on the gastric contents have beendesigned where buoyancy is created by low density of the formulationcomponents. For example, Watanabe et al (3) used low density shells suchas spherical polystyrene foam particles in which polymer and drug layerswere loaded. Such a system has the required low density and will notneed to disintegrate into small pieces to empty from the stomach, butmay not have a controlled loss of density alternatively required for itto eventually exit from the stomach. It also has limited capacity forloading with drug in the thin layers that can be applied around thepolystyrene shells. It would be difficult to also layer large amounts ofpolymer on such a system to retard the release of very water solubledrugs.

Sheth described hydrodynamically balanced systems including bothcapsules and tablets (4,5,6) which had low density to enable floating onthe stomach contents and which slowly eroded after administration,losing buoyancy and being expelled from the stomach.

Buoyancy can also be combined with control of drug release at differentpH values to make for a device with better control in case of drugs withvery marked dependency of solubility on pH (7); hence dissolution ofcontained drug depending on environment pH.

These approaches may be applicable to many drugs dosed in doses of up toa maximum of a few hundred milligrams per day but may not be applicableto similar or higher dose levels of highly water soluble drugs. Wherelarge amounts of polymer are needed to retard drug release as in thecase of use of high water soluble drugs a capsule dosage form may not bepossible on grounds of size. Furthermore, the relatively homogenousdistribution of drug in the tablet versions of this technology would notreadily control the burst effect seen with a very water soluble drug.

A bilayer tablet approach (8) where the buoyancy generation comes from aseparate layer to the drug containing layer having a release ratecontrolling property might overcome some of the problems seen with thehydrodynamically balanced systems, but this type of system wouldprobably only be able to carry low drug payloads due to sizeconstraints.

Approaches involving in situ gas generation within the system, where thegas is trapped within the dosage form on generation, encouragingbuoyancy, might offer improved control over degree, onset time andpersistence of buoyancy. Ichikawa (9) described such a device with adrug loaded core surrounded by the gas generating layer, which in turnwas surrounded by a polymeric layer responsible for controlling drugrelease from the system.

Such floating or buoyant dosage forms seem to have met with limitedclinical success due to the requirement that such dosage forms be takenwith a suitable amount of fluid (normal gastric contents could be aslittle as a few tens of milliliters so that the total amount of fluidthus available would not be conducive to performance of such systemseven when taken with a draught of water). Davis et al (10) found nobenefit of floating formulations over non-floating formulations whenstudied in vivo. Their performance may also be posture dependent. Apatient sitting upright may ensure prolonged gastric residence of abuoyant dosage form, whereas a supine patient might allow readypresentation of the floating dosage form to the pylorus and thus allowrapid exit of the dosage form from the stomach (11). The physical sizeof such dosage forms seems to be as important if not more important asability to float in encouraging prolonged gastric residence. Hence,floating/buoyant dosage forms might be expected to only have limitedapplications.

Re: (2) Bioadhesive Systems

Polycarbophil has been identified as a suitable polymer for encouragingadhesion of orally administered dosage forms to the gastric mucosa,thereby prolonging residence time for a system designed to slowlydeliver drug to absorptive sites in the proximal small intestine (Longeret al, J. Pharm. Sci., 74, 406-411 (1985)). The success seen in animalmodels with such systems has been found not to translate to humansubjects due to differences in mucous amounts, consistency and turnoverbetween animals and humans. Bioadhesive systems allow dosage forms toadhere to mucous, not mucosa. The mucous layer in humans would appear toslough off readily, carrying any dosage form with it. Therefore,bioadhesive dosage forms would not appear to offer a solution forextended delivery of drug over a period of more than a few hours to theupper small intestine in humans.

Re: (3) Swelling/expanding Systems

Other solutions to encouraging prolonged gastric residence have includeddosage forms that unfold rapidly within the stomach to a size thatresists gastric emptying. Such systems retain their integrity for anextended period and will not empty from the stomach at all untilbreakdown into small pieces occurs. Caldwell (12) describes a crossshaped device made of erodible polymer and loaded with drug which isfolded and inserted into a hard gelatin capsule. Following oraladministration the gelatin shell disintegrates and the folded deviceopens out. With a minimum size of 1.6 cm and a maximum size of 5 cm itwill not pass from the stomach through the pylorus until the polymererodes to the point where the system is sufficiently small that it canbe passed from the stomach. Such a system may in fact obstruct thepylorus or even open earlier or later than intended possibly causingobstruction in the esophagus or small intestine. As such, it mayrepresent a potential hazard to the patient.

An alternate approach to using size to modulate gastric residence of adosage form is to use a hydrophilic erodible polymer system that is of aconvenient size for administration to humans. On imbibing fluid thesystem swells over a short period of time to a size that will encourageprolonged gastric retention, allowing sustained delivery of containeddrug to absorption sites in the upper gastrointestinal tract. Becausethese systems are made of an erodible and hydrophilic polymer or polymermixture, they readily erode over a reasonable time period to pass fromthe stomach. The time period of expansion is such that this will notoccur in the esophagus and if the system passes into the intestine in apartially swollen state, the erodibility and elastic nature of thehydrated polymer will eliminate the chance of intestinal obstruction bythe device.

Mamajek et al, U.S. Pat. No. 4,207,890, describes a system wherein adrug release rate controlling (metering) component and a swellingcomponent are mixed with drug enclosed within a membrane. The swellingcomponent draws in fluid through the membrane, which maintains systemintegrity during its functioning, and the drug metering componentcontrols the rate of drug release through the membrane.

Urquart (13) describes a different approach which consists of a matrixof hydrogel that imbibes fluid to swell the system so that it reaches asize encouraging prolonged gastric retention. This matrix surrounds aplurality of tiny pills consisting of drug with a release ratecontrolling wall of fatty acid and wax surrounding each of the pills.

Shell (14,15,16) has described systems for delivering drugs for thetreatment of diseases of the upper gastrointestinal tract or fordelivering drugs that might be irritating or injurious to thegastrointestinal mucosa. A swelling hydrogel polymer has embedded withinit drug particles that dissolve once the hydrogel matrix is hydrated.The swollen matrix is of a size to encourage gastric retention but onlydissolved drug reaches the mucosa and this can be delivered in asustained manner. Such a system thus does not insult the mucosa withsolid particles of irritant drug and is suitable for delivering drug toupper gastrointestinal tract. These systems only apply in case of drugsof limited water solubility.

In the case of metformin, it is desirable to provide a dosage form thatallows extended delivery of the drug and has a prolonged gastricresidence via swelling of the system rather than unfolding or expandingof a folded device, and that may be manufactured on a commercial scale.The prolonged gastric residence time is required due to the window ofabsorption seen with metformin.

Another problem for extended delivery of metformin is its very highwater solubility. High levels of polymer would be needed if many priorart approaches to provide the required release rate are employed. Thiscould result in a rapid and variable initial release (burst) of drugfrom an extended release dosage form. The latter will thus give rise todifficulty in providing a true control of drug release and minimalinter-patient variability in drug plasma levels (arising from thepossibility of variable burst of drug from tablets given to differentpatients).

Prior Art Controlled Release Systems for Very Soluble Drugs

Typical prior art techniques for creating a controlled release oraldosage form would involve either matrix systems or multi particulatesystems. Matrix systems may be formulated by homogeneously mixing drugwith hydrophilic polymers, such as hydroxypropylmethylcellulose,hydroxypropylcellulose, polyethylene oxide, carbomer, certainmethacrylic acid derived polymers, sodium alginate, or mixtures ofcomponents selected from these, and compressing the resultant mixtureinto tablets (employing some other excipients where needed). Hydrophobicpolymers, such as ethyl cellulose, certain polymeric methacryllc acidesters, cellulose acetate butyrate, poly(ethylene-co-vinyl-acetate) maybe uniformly incorporated with the above materials to give additionalcontrol of release. A further alternative involves embedding drug withina wax based tablet, by granulation or simply mixing of drug with a wax,such as carnauba wax, microcrystalline wax or commercially availablepurified fatty acid esters. As noted above, it may not be possible touse these approaches with very highly water soluble drugs.

Multi particulate systems consist of a dosage form based on a pluralityof drug loaded spheres, prepared by layering drug onto a core, usually asugar-starch mixture sphere of around 0.8 mm diameter, until asufficient level is reached, and then providing a drug release barrieraround the drug-loaded sphere. Drug-loaded spheres can also be made bywet massing a mixture of drug and excipients, forcing the wet massthrough a perforated screen to form short strands which are rounded in aspheronisation apparatus before drying and having the drug releasebarrier applied. The drug release barrier can be a wax, such as carnaubawax or glyceryl fatty acid esters, or a polymeric barrier, such as amixture of ethyl cellulose and hydroxypropylmethylcellulose. These workwell for moderately soluble drugs with doses in the units of milligramsto less than a few hundred milligrams per day.

In several examples, prior art systems seem to provide a controlledrelease formulation of a very water soluble drug by improving the multiparticulate system approach. Fisher discloses a multi particulate systemfor highly soluble drugs especially opiate agonists (17) based on drugcontaining cores surrounded by a drug release controlling barrier whichhas the property of being partially soluble at a highly acidic pH.

Hansraj (18) coats drug loaded cores with methacrylic or acrylic acidderived polymers whose properties are modified by inclusion of at leastone anionic surfactant. In such a system, drug release of highly watersoluble drugs is controlled without having to resort to the use of thickcoatings on the release rate controlling layer.

Rollet (19) achieves prolonged release of a drug from a multiparticulate formulation based on fine particles of hydrophilic andhydrophobic silicas or silicates. Presumably, this system would functionfor drugs of high water solubility.

Multi particulate systems are usually filled into capsules to provideunit dose forms because of the damage caused to such particles in tryingto compress them into tablets. Total dose contained in a single unit isconstrained by the loading possible in a hard gelatin capsule of easilyswallowable size and is usually not more than a few hundred milligrams.

Single unit controlled release systems applicable to highly watersoluble drugs include the application of multiple layers around a doseform as described by Howard (20). Where coating is not employed, specialmixtures of polymers or formation of a complex with the drug have beenused. Macrae (21) uses mixtures of polyethylene oxide andhydroxypropylmethylcellulose with optional enteric polymers to produce aconstant release rate for highly water soluble drugs. Belenduik (22)combines the highly water soluble drug with a hydrophilic polymer basedon acrylic acid and disperses this in a hydrophobic matrix.

Variations of Alza osmotic systems have been described suitable forhighly water soluble drugs such as venlafaxine hydrochloride (23). Thesesystems need two layers, a drug layer and an osmotically drivendisplacement layer all surrounded by a water permeable/drug impermeablemembrane with an exit passage in this membrane for the drug.

Granules of highly water soluble clavulanate were prepared (24) havingto employ a barrier layer of a hydrophobic waxy material in order toprovide for controlled release of this material when co-formulated withcontrolled release amoxycillin trihydrate granules in capsule orcompressed tablet.

DESCRIPTION OF THE INVENTION

In accordance with the present invention, a novel way has been found offormulating drug with high water solubility and a limited window ofabsorption such as metformin or a salt thereof which has a window ofabsorption in the upper gastrointestinal tract, to provide a dosage formthat inherently has prolonged gastric residence. This is accomplished(a) without need for co-administration of a drug such as propantheline,and (b) without need for low density formulation or gas generationwithin the formulation, The formulation of the invention (a) achievesextended gastric residence by virtue of size but will degrade in vivo soas not to have potential for causing gastric or intestinal obstruction,and (b) controls drug release adequately where the initial burst of drugis under control. The formulations of the invention will provide for anextended release formulation of drug with minimal interpatientvariability in pharmacokinetic parameters.

In the case of metformin, the formulation of the invention allows apatient a dosing regimen of at least one gram metformin, once-daily,preferably from about 1 to about 3 grams, once daily, in the form of oneor more tablets and/or one or more capsules, while providing effectivecontrol of plasma glucose. The metformin formulations of the inventionmay be administered once daily at the above dosages to effectively treatdiabetes while avoiding problems which may be associated with highplasma metformin levels as may be encountered with conventionalmetformin formulations, while providing optimum therapeutic control.

The invention is applicable to all drugs having high water solubilityand a limited window of absorption.

The biphasic controlled release delivery system of the invention is aheterogeneous two phase system which includes (1) an inner solidparticulate phase in the form of individual granules or particlescontaining (a) drug which has a high water solubility, preferably,metformin or a salt thereof, and a limited window of absorption (such asin the upper gastrointestinal tract), and (b) an extended releasematerial formed of one or more hydrophilic polymers, and/or one or morehydrophobic polymers, and/or one or more other type hydrophobicmaterials (such as one or more waxes, fatty alcohols and/or fatty acidesters), and (2) an outer solid continuous phase in which granules orparticles of inner solid particulate phase are dispersed and embedded,the outer solid continuous phase which primarily is formed of anextended release material formed of one or more hydrophilic polymers,and/or one or more hydrophobic polymers, and/or one or more other typehydrophobic materials (such as one or more waxes, fatty alcohols and/orfatty acid esters).

The biphasic controlled release formulation of the invention isparticularly adapted for delivery of high water soluble drugs, such asmetformin and pharmaceutically acceptable salts thereof, in controlledand extended manner without significant initial burst of drug, andwherein release of drug (liberated from the individual dispersedparticles forming the inner solid particulate phase) is effectivelycontrolled. Drug upon being released from the particles of the innerphase, in effect, migrates through the outer solid continuous phase andthen is released from the formulation into the upper gastrointestinaltract to be available for absorption.

As indicated, the inner solid particulate phase will be formed ofindividual discrete particles or granules each of which contains drugand one or more polymeric materials and/or other hydrophobic-typematerials. In effect, the components of the inner solid particulatephase are in particulate association without having a barrier layeraround the individual particles or granules.

The outer solid continuous phase is preferably a continuous phase ormatrix having the particles or granules including drug (forming theinner solid phase) dispersed throughout and embedded in the continuousouter solid phase.

In addition, in accordance with the present invention, a method forlowering insulin resistance or treating diabetes is provided wherein thebiphasic controlled release formulation of the invention containing anantidiabetic pharmaceutical is administered to a patient in need oftreatment.

The term “diabetes” as employed herein refers to type 2 diabetes andtype 1 diabetes, usually type 2 diabetes.

The antidiabetic pharmaceutical employed is preferably a biguanide,preferably metformin or a pharmaceutically acceptable salt thereof suchas the hydrochloride, hydrobromide, fumarate, succinate, p-chlorophenoxyacetate or embonate, all of which are collectively referred to asmetformin. The fumarate and succinate salts are preferably the metformin(2:1) fumarate, and the metformin (2:1) succinate disclosed in U.S.application Ser. No. 09/262,526 filed Mar. 4, 1999. Metforminhydrochloride salt is preferred.

In another aspect of the present invention, a method is provided forlowering insulin resistance or treating diabetes wherein the biphasiccontrolled release formulation of the invention contains metformin andis administered in a dosing regimen of at least one gram metformin, oncedaily, preferably from about 1 to about 3 grams, once daily, to apatient in need of treatment.

The term “extended release material” as present in the inner solidparticulate phase and the outer solid continuous phase refers to one ormore hydrophilic polymers and/or one or more hydrophobic polymers and/orone or more other type hydrophobic materials, such as, for example, oneor more waxes, fatty alcohols and/or fatty acid esters. The “extendedrelease material” present in the inner solid particulate phase may bethe same as or different from the “extended release material” present inthe outer solid continuous phase. However, it is preferred that the“extended release material” present in the inner solid particulate phasebe different from the “extended release material” present in the outersolid continuous phase.

The term “high water solubility” or similar term when characterizing adrug, medicament or pharmaceutical for use in the formulation of theinvention refers to a solubility in water at ambient temperature of atleast about 50 mg/ml H₂O, preferably at least about 100 mg/ml H₂O ormore, and more preferably greater than 150 mg/ml.

The term “limited window of absorption” or similar term whencharacterizing a drug, medicament or pharmaceutical for use in theformulation of the invention refers to an oral bioavailability of lessthan about 75%, usually less than about 60%, usually decreasing withincreasing dose, and almost invariably having permeability/transit timelimited absorption.

The biphasic controlled release system of the invention will include theinner solid particulate phase in a weight ratio to the outer solidcontinuous phase within the range from about 0.5:1 to about 4:1,preferably from about 0.8:1 to about 2:1.

The inner solid particulate phase will contain drug in an amount withinthe range from about 10 to about 98% by weight, preferably from about 15to about 95% by weight, and extended release material in the form ofhydrophilic polymers and/or hydrophobic polymers and/or otherhydrophobic material in an amount within the range from about 5 to about95% by weight, preferably from about 7 to about 85% by weight, the above% being based on the weight of the inner solid particulate phase. Wheremixtures are employed, the hydrophilic polymer will be employed in aweight ratio to hydrophobic polymer and/or other hydrophobic materialwithin the range from about 0.05:1 to about 19:1, preferably from about0.1:1 to about 10:1.

The particles or granules of the inner solid particulate phase will havea mean particle size within the range from about 30 μm to about 0.8 mm,and preferably from about 50 μm to about 0.5 mm.

The outer solid continuous phase will contain extended release material(preferably different from that employed in the inner solid particulatephase) in the form of one or more hydrophilic polymers and/orhydrophobic polymers and/or other hydrophobic material in an amountwithin the range from about 40 to about 100%, preferably from about 60to about 100% (based on the weight of the outer solid continuous phase).

The outer solid continuous phase may contain mixtures of two or moreextended release materials in the form of one or more hydrophilicpolymer and/or hydrophobic polymer and/or other hydrophobic material ina weight ratio of hydrophilic polymer to hydrophobic polymer or otherhydrophobic material within the range from about 200:1 to about 0.05:1,preferably from about 100:1 to about 0.1:1.

The pharmaceutical formulation of the invention will have a totalpolymer extended release material content (including hydrophilicpolymers and/or hydrophobic polymers and/or other hydrophobic materialpresent in the inner solid particulate phase and hydrophilic polymerand/or hydrophobic polymers and/or other hydrophobic material present inthe outer solid continuous phase) within the range from about 25 toabout 75% by weight, preferably from about 30 to about 65%, morepreferably from about 35 to about 60% by weight based on the totalweight of the pharmaceutical formulation.

Hydrophilic polymers which may be employed in the inner solidparticulate phase and/or outer solid continuous phase include, but arenot limited to hydroxypropylmethylcellulose, hydroxypropylcellulose,sodium carboxymethylcellulose, carboxymethylcellulose calcium, ammoniumalginate, sodium alginate, potassium alginate, calcium alginate,propylene glycol alginate, alginic acid, polyvinyl alcohol, povidone,carbomer, potassium pectate, potassium pectinate, and the like.

Hydrophobic polymers which may be employed in the inner solidparticulate phase and/or outer solid continuous phase include, but arenot limited to ethyl cellulose, hydroxyethylcellulose, ammoniomethyacrylate copolymer (Eudragit RL™ or Eudragit RS™), methyacrylicacid copolymers (Eudragit L™ or Eudragit S™), methacrylic acid-acrylicacid ethyl ester copolymer (Eudragit L 100-5™), methacrylic acid estersneutral copolymer (Eudragit NE 30D™),dimethylaminoethylmethacrylate-methacrylic acid esters copolymer(Eudragit E 100™), vinyl methyl ether/maleic anhydride copolymers, theirsalts and esters (Gantrez™).

Other hydrophobic materials which may be employed in the inner solidparticulate phase and/or outer solid continuous phase include, but arenot limited to waxes such as beeswax, carnauba wax, microcrystallinewax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearylalcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters suchas glyceryl monostearate, glycerol monooleate, acetylatedmonoglycerides, tristearin, tripalmitin, cetyl esters wax, glycerylpalmitostearate, glyceryl behenate, and hydrogenated castor oil.

Where hydrophilic polymers and/or hydrophobic polymers are used in theinner solid particulate phase and/or the outer solid continuous phase,such polymers can be ionic or non-ionic, preferably ionic for the innersolid particulate phase and preferably non-ionic for the outer solidcontinuous phase.

Preferred ionic polymers for use in the inner solid particulate phaseinclude sodium alginate, carbomer (Carbopol™), calciumcarboxymethylcellulose, or sodium carboxymethylcellulose, xanthan gum,methacrylic acid-acrylic acid ethyl ester copolymer,dimethylaminoethylmethacrylate-methacrylic acid esters copolymer,cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate,hydroxypropylmethylcellulose trimellitate, andhydroxypropylmethylcellulose maleate, with sodium carboxymethylcellulosebeing particularly preferred.

Preferred non-ionic polymers for use in the outer solid continuous phaseare those which assure rapid hydration of the outer solid continuousphase to minimize a variable and significant burst of drug, yeteffectively control the release of drug being liberated from thediscrete particles or granules forming the inner solid particulatephase. The liberated drug will migrate through the non-ionic polymersforming the outer solid continuous phase before being released from thedosage form and being available for absorption. Preferred polymers forthe outer solid phase with the appropriate hydration characteristicsinclude hydroxypropylmethyl cellulose 2208 USP(hydroxypropylmethylcellulose with a methoxyl content of 19-24% and ahydroxypropyl content of 4-12%), viscosity grades ranging from about4000 to about 100,000 cps and hydroxypropylmethylcellulose 2910 USP(hydroxypropyl-methylcellulose with a methoxy content of 28-30% and ahydroxypropyl content of 7-12%), viscosity grades ranging from about 3to about 150 cps. In particular preferred embodiments of the outer solidphase, the above preferred polymers are used in admixture in weightratios of hydroxypropylmethylcellulose 2208USP:hydroxypropylmethylcellulose 2910 USP within the range from about25:1 to about 50:1, preferably from about 30:1 to about 40:1.

Preferred biphasic controlled extended release delivery systems inaccordance with the present invention are as follows.

% by Weight of Inner A. Inner Solid Particulate Phase Solid ParticulatePhase (1) Metformin HCl (or other 55 to 98  salt such as succinate orfumarate) (2) Polymer or Hydrophobic 5 to 95 Material Preferred:ethylcellulose and/or 5 to 45 sodium carboxymethylcellulose and/orglyceryl monostearate (Average Particle Size of granules forming innersolid particulate phase: 0.05 to 2.0 mm) % by Weight of Outer B. OuterSolid Continuous Phase Solid Continuous Phase Polymer and/or Hydrophobic40 to 100 Material: Preferred (1) Hydroxypropylmethyl- 60 to 100cellulose 2208USP (100,000 cps) (2) Hydroxypropylmethyl 1 to 30cellulose 2910 USP (5 cps) Weight Ratio of Inner Solid Phase: 0.5:1 to1.5:1  Outer Solid Phase % by Weight of Outer C. Optional IngredientsSolid Continuous Phase Lubricant (e.g. Mg Stearate) 0.02 to 1   Compression aid (e.g. 0 to 30 Microcrystalline cellulose)

The preferred drug (having high water solubility) or use herein ismetformin or pharmaceutically acceptable salts thereof, including thehydrochloride salt and dibasic salts such as metformin (2:1) fumarateand metformin (2:1) succinate as described in pending U.S. applicationSer. No. 09/262,526 filed Mar. 4, 1999, now U.S. Pat. No. 6,031,044,which is incorporated herein by reference.

Most preferred are the metformin hydrochloride salt, metformin (2:1)succinate salt, and metformin (2:1) fumarate salt.

Where desired, metformin or a salt thereof may be used in combinationwith another antihyperglycemic agent and/or a hypolipidemic agent whichmay be administered orally in the same dosage form in accordance withthe invention, a separate oral dosage form or by injection. Themetformin or salt thereof will be employed in a weight ratio to theother antihyperglycemic agent and/or hypolipidemic agent within therange from about 0.01:1 to about 300:1, preferably from about 0.05:1 toabout 250:1.

It is believed that the use of the metformin or salt thereof incombination with another antihyperglycemic agent producesantihyperglycemic results greater than that possible from each of thesemedicaments alone and greater than the combined additiveantihyperglycemic effects produced by these medicaments.

In addition, in accordance with the present invention a method isprovided for lowering insulin resistance or treating hyperglycemiaincluding type 2 diabetes (NIDDM) and/or type 1 diabetes (IDDM) whereina therapeutically effective amount of the biphasic formulation of theinvention containing metformin or a salt thereof, optionally incombination with another antihyperglycemic agent and/or a hypolipidemicagent, is administered to a patient in need of treatment.

The other antihyperglycemic agent may be an oral antihyperglycemic agentpreferably a sulfonyl urea such as glyburide (also known asglibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785),glipizide, gliclazide or chlorpropamide, other known sulfonylureas orother antihyperglycemic agents which act on the ATP-dependent channel ofthe β-cells, with glyburide being preferred.

The metformin or salt thereof will be employed in a weight ratio to thesulfonyl urea in the range from about 300:1 to about 50:1, preferablyfrom about 250:1 to about 75:1.

The oral antihyperglycemic agent may also be a glucosidase inhibitorsuch as acarbose (disclosed in U.S. Pat. No. 4,904,769) or miglitol(disclosed in U.S. Pat. No. 4,639,436), which may be administered in aseparate oral dosage form.

The metformin salt thereof will be employed in a weight ratio to theglucosidase inhibitor within the range from about 300:1 to about 2:1,preferably from about 200:1 to about 25:1.

The metformin or salt thereof may be employed in combination with athiazolidinedione oral anti-diabetic agent (which has an insulinsensitivity effect in NIDDM patients) such as troglitazone(Warner-Lambert's Rezulin®, disclosed in U.S. Pat. No. 4,572,912),rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555(disclosed in U.S. Pat. No. 5,594,016) Glaxo-Welcome's GL-262570,englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer).

The metformin or salt thereof will be employed in a weight ratio to thethiazolidinedione in an amount within the range from about 75:1 to about0.1:1, preferably from about 5:1 to about 0.5:1.

The sulfonyl urea and thiazolidinedione in amounts of less than about150 mg oral anti-diabetic agent may be incorporated in a single tabletwith the biphasic controlled release formulation of the invention as aseparate rapidly dissolving layer.

The metformin or salt thereof may also be employed in combination with anon-oral antihyperglycemic agent such as insulin or with glucagon-likepeptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) amide,GLP-1(7-37) (as disclosed in U.S. Pat. No. 5,614,492 to Habener, thedisclosure of which is incorporated herein by reference), which may beadministered via injection, or by transdermal or buccal devices.

Where present, the sulfonyl ureas, such a s glyburide, glimepiride,glipyride, glipizide, glipizide, chlorpropamide and gliclazide and theglucosidase inhibitors acarbose or miglitol may be employed informulations as described above and in amounts and dosing as indicatedin the Physician's Desk Reference.

Where present, the thiazolidinedione anti-diabetic agent may be employedin amounts within the range from about 0.01 to about 2000 mg/day whichmay be administered in single or divided doses one to four times perday.

Where present insulin may be employed in formulations, amounts anddosing as indicated by the Physician's Desk Reference.

Where present GLP-1 peptides may be administered in oral buccalformulations, by nasal administration or parenterally as described inU.S. Pat. No. 5,346,701 (TheraTech), U.S. Pat. Nos. 5,614,492 and5,631,224 which are incorporated herein by reference.

The hypolipidemic agent which may be optionally employed in combinationwith metformin or a salt thereof may include MTP inhibitors, HMG CoAreductase inhibitors, squalene synthetase inhibitors, fibric acidderivatives, ACAT inhibitors, cholesterol absorption inhibitors, ilealNa⁺/bile acid cotransporter inhibitors, bile acid sequestrants, and/ornicotinic acid and derivatives thereof.

MTP inhibitors employed herein include MTP inhibitors disclosed in U.S.Pat. No. 5,595,872, U.S. Pat. No. 5,739,135, U.S. Pat. No. 5,712,279,U.S. Pat. No. 5,760,246, U.S. Pat. No. 5,827,875, U.S. Pat. No.5,885,983 and U.S. application Ser. No. 09/175,180 filed Oct. 20, 1998,now U.S. Pat. No. 5,563,440. Preferred are each of the preferred MTPinhibitors disclosed in each of the above patents and applications.

All of the above U.S. Patents and applications are incorporated hereinby reference.

Most preferred MTP inhibitors to be employed in accordance with thepresent invention include preferred MTP inhibitors as set out in U.S.Pat. Nos. 5,739,135 and 5,712,279, and U.S. Pat. No. 5,760,246.

The most preferred MTP inhibitor is

9-[4-[4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide

The hypolipidemic agent may be an HMG CoA reductase inhibitor whichincludes, but is not limited to, mevastatin and related compounds asdisclosed in U.S. Pat. No. 3,983,140, lovastatin (mevinolin) and relatedcompounds as disclosed in U.S. Pat. No. 4,231,938, pravastatin andrelated compounds such as disclosed in U.S. Pat. No. 4,346,227,simvastatin and related compounds as disclosed in U.S. Pat. Nos.4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may beemployed herein include, but are not limited to, fluvastatin, disclosedin U.S. Pat. No. 5,354,772, cerivastatin disclosed in U.S. Pat. Nos.5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Pat. Nos.4,681,893, 5,273,995, 5,385,929 and 5,686,104, pyrazole analogs ofmevalonolactone derivatives as disclosed in U.S. Pat. No. 4,613,610,indene analogs of mevalonolactone derivatives as disclosed in PCTapplication WO 86/03488,6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivativesthereof as disclosed in U.S. Pat. No. 4,647,576, Searle's SC-45355 (a3-substituted pentanedioic acid derivative) dichloroacetate, imidazoleanalogs of mevalonolactone as disclosed in PCT application WO 86/07054,3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed inFrench Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan andthiophene derivatives as disclosed in European Patent Application No.0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Pat.No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Pat. No.4,499,289, keto analogs of mevinolin (lovastatin) as disclosed inEuropean Patent Application No. 0,142,146 A2, as well as other known HMGCoA reductase inhibitors.

In addition, phosphinic acid compounds useful in inhibiting HMG CoAreductase suitable for use herein are disclosed in GB 2205837.

The squalene synthetase inhibitors suitable for use herein include, butare not limited to, α-phosphonosulfonates disclosed in U.S. Pat. No.5,712,396, those disclosed by Biller et al, J. Med. Chem., 1988, Vol.31, No. 10, pp 1869-1871, including isoprenoid(phosphinylmethyl)phosphonates as well as other squalene synthetaseinhibitors as disclosed in U.S. Pat. Nos. 4,871,721 and 4,924,024 and inBiller, S. A., Neuenschwander, K., Ponpipom, M. M., and Poulter, C. D.,Current Pharmaceutical Design, 2, 1-40 (1996).

In addition, other squalene synthetase inhibitors suitable for useherein include the terpenoid pyrophosphates disclosed by P. Ortiz deMontellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyldiphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs asdisclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293,phosphinylphosphonates reported by McClard, R. W. et al, J.A.C.S., 1987,109, 5544 and cyclopropanes reported by Capson, T. L., PhD dissertation,June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp16, 17, 40-43, 48-51, Summary.

Other hypolipidemic agents suitable for use herein include, but are notlimited to, fibric acid derivatives, such as fenofibrate, gemfibrozil,clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like,probucol, and related compounds as disclosed in U.S. Pat. No. 3,674,836,probucol and gemfibrozil being preferred, bile acid sequestrants such ascholestyramine, colestipol and DEAE-Sephadex (Secholex®, Policexide®),as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substitutedethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL),istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (TanabeSeiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo),Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546(disubstituted urea derivatives), nicotinic acid, acipimox, acifran,neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine)derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternaryamine poly(diallyldimethylammonium chloride) and ionenes such asdisclosed in U.S. Pat. No. 4,027,009, and other known serum cholesterollowering agents.

The hypolipidemic agent may be an ACAT inhibitor such as disclosed in,“The ACAT inhibitor, Cl-1011 is effective in the prevention andregression of aortic fatty streak area in hamsters”, Nicolosi et al,Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; “Thepharmacological profile of FCE 27677: a novel ACAT inhibitor with potenthypolipidemic activity mediated by selective suppression of the hepaticsecretion of ApoB100-containing lipoprotein”, Ghiselli, Giancarlo,Cardiovasc. Drug Rev. (1998), 16(1), 16-30; “RP 73163: a bioavailablealkylsulfinyl-diphenylimidazole ACAT inhibitor”, Smith, C., et al,Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; “ACAT inhibitors:physiologic mechanisms for hypolipidemic and anti-atheroscleroticactivities in experimental animals”, Krause et al, Editor(s): Ruffolo,Robert R., Jr.; Hollinger, Mannfred A., Inflammation: Mediators Pathways(1995), 173-98, Publisher: CRC, Boca Raton, Fla.; “ACAT inhibitors:potential anti-atherosclerotic agents”, Sliskovic et al, Curr. Med.Chem. (1994), 1(3), 204-25; “Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents. 6. The firstwater-soluble ACAT inhibitor with lipid-regulating activity. Inhibitorsof acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of aseries of substituted N-phenyl-N′-[(1-phenylcyclopentyl)methyl]ureaswith enhanced hypocholesterolemic activity”, Stout et al, Chemtracts:Org. Chem. (1995), 8(6), 359-62.

The cholesterol absorption inhibitor may be Schering-Plough's SCH 48461or as disclosed in Atherosclerosis 115, 45-63 (1995) or J. Med. Chem.41, 973 (1998).

The ileal Na⁺/bile acid cotransporter inhibitor may be as disclosed inDrugs of the Future, 24, 425-430 (1999).

Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin,atorvastatin, fluvastatin and cerivastatin.

The above-mentioned U.S. patents are incorporated herein by reference.The amounts and dosages employed will be as indicated in the Physician'sDesk Reference and/or in the patents set out above.

The compounds of formula I of the invention will be employed in a weightratio to the hypolypidemic agent (were present), within the range fromabout 500:1 to about 1:500, preferably from about 100:1 to about 1:100.

The dose administered must be carefully adjusted according to age,weight and condition of the patient, as well as the route ofadministration, dosage form and regimen and the desired result.

The dosages and formulations for the hypolipidemic gent will be asdisclosed in the various patents, papers and applications discussedabove.

The dosages and formulations for the other hypolipidemic agent to beemployed, where applicable, will be as set out in the latest edition ofthe Physicians' Desk Reference.

For oral administration, a satisfactory result may be obtained employingthe MTP inhibitor in an amount within the range of from about 0.01 mg/kgto about 100 mg/kg and preferably from about 0.1 mg/kg to about 75mg/kg, one to four times daily.

A preferred oral dosage form, such as tablets or capsules, will containthe MTP inhibitor in an amount of from about 1 to about 500 mg,preferably from about 2 to about 400 mg, and more preferably from about5 to about 250 mg, one to four times daily.

For parenteral administration, the MTP inhibitor will be employed in anamount within the range of from about 0.005 mg/kg to about 10 mg/kg andpreferably from about 0.005 mg/kg to about 8 mg/kg, one to four timesdaily.

For oral administration, a satisfactory result may be obtained employingan HMG CoA reductase inhibitor, for example, pravastatin, lovastatin,simvastatin, atorvastatin, fluvastatin or cerivastatin in dosagesemployed as indicated in the Physician's Desk Reference, such as in anamount within the range of from about 1 to 2000 mg, and preferably fromabout 4 to about 200 mg.

The squalene synthetase inhibitor may be employed in dosages in anamount within the range of from about 10 mg to about 2000 mg andpreferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as tablets or capsules, will containthe HMG CoA reductase inhibitor in an amount from about 0.1 to about 100mg, preferably from about 5 to about 80 mg, and more preferably fromabout 10 to about 40 mg.

A preferred oral dosage form, such as tablets or capsules will containthe squalene synthetase inhibitor in an amount of from about 10 to about500 mg, preferably from about 25 to about 200 mg.

The metformin or salt thereof and the hypolipidemic agent may beemployed together in the same oral dosage form or in separate oraldosage forms taken at the same time.

The compositions described above may be administered in the dosage formsas described above in single or divided doses, once daily and up to fourtimes daily. It may be advisable to start a patient on a low dosecombination and work up gradually to a high dose combination.

The preferred hypolipidemic agent is pravastatin, simvastatin,lovastatin, atorvastatin, fluvastatin or cerivastatin.

The following additional type high water soluble drugs may be employedin the biphasic controlled release delivery system of the invention:

pravastatin;

antihypertensives and antidepressants related to guanethidine (asdisclosed in U.S. Pat. No. 2,928,829) and related to guanoxyfen (asdisclosed in BE612362);

antibiotics and viricides such as related to amidinomycin (as disclosedin JP 21,418);

stallimycin (as disclosed in DE 1,039,198);

Arphamenine B (as disclosed in published European Patent Application85/133550A2);

chitinovorin-A (as disclosed in published European Patent Application85/150,378A2 and U.S. Pat. No., 4,723,004);

streptomycin (as disclosed in U.S. Pat. No. 2,868,779);

SB-59 (as disclosed in Justus Liebigs, Ann. Chem. (1973) 7, 1112-1140);

TAN-1057-A (as disclosed in U.S. Pat. No. 4,971,965);

streptoniazid (as disclosed in J. Am. Chem. Soc. (1953) 75, 2261);

immunostimulants related to ST-789 (as disclosed in published EuropeanPatent Application 88/260588);

peptide hydrolase inhibitors related to nafamastat (as disclosed in U.S.Pat. No. 4,454,338);

gabexate (as disclosed in U.S. Pat. No. 3,751,447);

sepimostat (as disclosed in U.S. Pat. Nos. 4,777,182 and 4,820,730);

Factor Xa inhibitors related to DX-9065a (as disclosed in publishedEuropean Patent Application 92/0540051);

anti-inflammatory agents related to paranyline as disclosed in U.S. Pat.No. 2,877,269;

peptidyl aldehydes (as disclosed in WO94/13693);

antianaphylactics related to GMCHA-TBP (Batebulast) (as disclosed inU.S. Pat. No. 4,465,851);

anti-ulcer agents related to benexate (as disclosed in U.S. Pat. No.4,348,410);

deoxyspergualin (as disclosed in U.S. Pat. Nos. 4,518,532, 4,658,058 and4,983,328); and arginine.

Other water-soluble drugs suitable for use herein include peptidespreferably have a molecular weight from about 100 to 10,000, morepreferably from about 100 to about 6,000 and having from 2 to 35 aminoacid moieties. Higher molecular weight peptides, even those with amolecular weight of above 10,000, up to about 50,000, may also beaccommodated in biphasic formulations of the present invention.

Suitable small peptides have from about 2 to about 10, more preferablyfrom about 2 to about 6 amino acid moieties. Preferred small peptidesinclude the fibrinogen receptor antagonists (RGD containing peptides)which are tetrapeptides with an average molecular weight of about 600.These peptide antagonists are highly potent platelet aggregationinhibitors at plasma levels as low as 1 pmol/mL. Preferred fibrinogenantagonists include the peptidecyclo(S,S)-N^(a)-acetyl-Cys-(N^(a)-methyl)Arg-Gly-Asp-Pen-NH₂ (Ali etal, EP 0341915, whose disclosure is herein incorporated by reference)and the peptidecyclo(S,S)-(2-mercapto)benzoyl-(N^(a)-methyl)Arg-Gly-Asp-(2-mercapto)-phenylamide(EP 0423212:, whose disclosure is herein incorporated by reference).Other fibrinogen antagonists useful in the present invention are thosepeptides disclosed by Pierschbacher et al, WO 89/05150 (US/88/04403);Marguerie, EP 0275748; Adams et al, U.S. Pat. No. 4,857,508; Zimmermanet al, U.S. Pat. No. 4,683,291; Nutt et al, EP 0410537, EP 0410539, EP0410540, EP 0410541, EP 0410767, EP 0410833, EP 0422937 and EP 0422938;Ali et al, EP 0372486; Ohba et al, WO 90/02751 (PCT/JP89/00926); Kleinet al, U.S. Pat. No. 4,952,562; Scarborough et al, WO 90/15620(PCT/US90/03417); Ali et al, PCT/US90/06514 and PCT/US92/00999; thepeptide-like compounds disclosed by Ali et al, EP 0381033 and EP0384362; and the RGD peptidecyclo-N^(a)-acetyl-Cys-Asn-Dtc-Amf-Gly-Asp-Cys-OH (in which Dtc is4,4′-dimethylthia-zolidine-5-carboxylic acid and Amf is4-aminomethylphenyl-alanine).

The RGD peptide may be usefully included in the formulation of theinvention in an amount up to about 600 mg/g of the hydrophilic phase orfrom 0.1 to 60 mg/g of the formulation.

Other peptides useful in the present invention include, but are notlimited to, other RGD containing peptides such as those disclosed byMomany, U.S. Pat. No. 4,411,890 and U.S. Pat. No. 4,410,513; Bowers etal, U.S. Pat. No. 4,880,778, U.S. Pat. No. 4,880,777, U.S. Pat. No.4,839,344; and WO 89/10933 (PCT/US89/01829); the peptideAla-His-D-Nal-Ala-Trp-D-Phe-Lys-NH₂ (in which Na1 representsb-naphthyl-alanine) and the peptides disclosed by Momany, U.S. Pat. No.4,228,158, U.S. Pat. No. 4,228,157, U.S. Pat. No. 4,228,156, U.S. Pat.No. 4,228,155, U.S. Pat. No. 4,226,857, U.S. Pat. No. 4,224,316, U.S.Pat. No. 4,223,021, U.S. Pat. No. 4,223,020, U.S. Pat. No. 4,223,019 andU.S. Pat. No. 4,410,512.

Other suitable peptides include hexapeptides such as the growth hormonereleasing peptide (GHRP) His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, (Momany, U.S.Pat. No. 4,411,890, the disclosure of which is herein incorporated byreference in its entirety). This may usefully be included in an amountup to about 250 mg/g of the hydrophilic phase or from 0.1 to 25 mg/kg ofthe formulation.

Suitable larger polypeptides and proteins for use in the controlledrelease formulations of the present invention include insulin,calcitonin, elcatonin, calcitoningene related peptide and porcinesomatostatin as well as analogs and homologs thereof. Other suitablelarger polypeptides include those disclosed by Pierschbacher et al, U.S.Pat. No. 4,589,881 (>30 residues); Bittle et al, U.S. Pat. No. 4,544,500(20-30 residues); and Dimarchi et al, EP 0204480 (>34 residues).

Other type of compounds useful in the present invention include analogsor homologs of LHRH which display potent LH releasing activity orinhibit the activity of LHRH; analogs or homologs of HP5 which possesseshematopoetic activity; analogs or homologs of endothelin which possesshypotensive activity; analogs or homologs of enkephalin which haveantinociceptive activity; analogs or homologs of chlorecystokinin;analogs or homologs of cyclosporin A which have immunosuppressiveactivity; analogs or homologs of atrial natriuretic factor; peptidergicantineoplastic agents; analogs or homologs of gastrin releasing peptide;analogs or homologs of somatostatin; gastrin antagonists; bradykininantagonists; neurotensin antagonists; bombesin antagonists; oxytocinagonists and antagonists; vasopressin agonists and antagonists; hirudinanalogs and homologs; analogs and homologs of the cytoprotectivepeptidecyclolinopeptide; alpha MSH analogs; analogs, and homologs of MSHreleasing factor (Pro-Leu-Gly-NH₂); peptides which inhibit collagenase;peptides which inhibit elastase, peptides which inhibit renin; peptideswhich inhibit HIV protease; peptides which inhibit angiotensinconverting enzyme; peptides which inhibit chymases and tryptases andpeptides which inhibit blood coagulation enzymes.

Other suitable drugs include non-peptide therapeutic agents such asantibiotics, antimicrobial agents, antineoplastic agents, cardiovascularand renal agents, such as captopril, anti-inflammatory,immunosuppressive and immunostimulatory agents and CNS agents.

Preferably, the water-soluble drug is metformin or salt thereof asdescribed above.

The biphasic controlled release formulation of the present invention canbe administered to various mammalian species, such as dogs, cats,humans, etc., in need of such treatment.

The biphasic controlled release system of the invention can beincorporated in a conventional systemic dosage form, such as a tablet orcapsule. The above dosage forms may also include the necessaryphysiologically acceptable carrier material, excipient, lubricant,buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants(ascorbic acid or sodium bisulfite) or the like.

The dose administered must be carefully adjusted according to the age,weight, and condition of the patient, as well as the route ofadministration, dosage form and regimen, and the desired result. Ingeneral, the dosage forms of formulation containing metformin or saltthereof (whether by itself or with another antihyperglycemic agentand/or a hypolipidemic agent) described above may be administered inamounts as described for metformin hydrochloride (Bristol-Myers SquibbCompany's Glucophage®) as set out in the Physician's Desk Reference.

The combination of the metformin or salt thereof and the otherantihyperglycemic agent and/or hypolipidemic agent may be formulatedseparately or, where possible, in a single formulation employingconventional formulation procedures.

The various formulations of the invention may optionally include one ormore fillers or excipients in an amount within the range of from about 0to about 90% by weight and preferably from about 1 to about 80% byweight such as lactose, sugar, corn starch, modified corn starch,mannitol, sorbitol, inorganic salts such as calcium carbonate and/orcellulose derivatives such as wood cellulose and microcrystallinecellulose (also referred to as a compression aid).

One or more binders may be present in addition to or in lieu of thefillers in an amount within the range of from about 0 to about 35% andpreferably from about 0.5 to about 30% by weight of the composition.Examples of such binders which are suitable for use herein includepolyvinylpyrrolidone (molecular weight ranging from about 5000 to about80,000 and preferably about 40,000), lactose, starches such as cornstarch, modified corn starch, sugars, gum acacia and the like as well asa wax binder in finely powdered form (less than 500 microns) such ascarnauba wax, paraffin, spermaceti, polyethylenes or microcrystallinewax.

Where the composition is to be in the form of a tablet, it will includeone or more tableting lubricants in an amount within the range of fromabout 0.2 to about 8% and preferably from about 0.5 to about 2% byweight of the composition, such as magnesium stearate, stearic acid,palmitic acid, calcium stearate, talc, carnauba wax and the like. Otherconventional ingredients which may optionally be present includepreservatives, stabilizers, anti-adherents or silica flow conditionersor glidants, such as Syloid brand silicon dioxide as well as FD&Ccolors.

Tablets of the invention may also optionally include an optional coatinglayer which may comprise from 0 to about 15% by weight of the tabletcomposition. The coating layer which is applied over the outer solidphase containing particles of inner solid phase embedded therein maycomprise any conventional coating formulations and will include one ormore film-formers or binders, such as a hydrophilic polymer likehydroxypropylmethylcellulose, and/or a hydrophobic polymer likemethacrylic acid esters neutral polymer, ethyl cellulose, celluloseacetate, polyvinyl alcohol-maleic anhydride copolymers, β-pinenepolymers, glyceryl esters of wood resins and the like and one or moreplasticizers, such as triethyl citrate, diethyl phthalate, propyleneglycol, glycerin, butyl phthalate, castor oil and the like. Both coretablets as well as coating formulations may contain aluminum lakes toprovide color.

The film formers are applied from a solvent system containing one ormore solvents including water, alcohols like methyl alcohol, ethylalcohol or isopropyl alcohol, ketones like acetone, or ethylmethylketone, chlorinated hydrocarbons like methylene chloride,dichloroethane, and 1,1,1-trichloroethane.

Where a color is employed, the color will be applied together with thefilm former, plasticizer and solvent compositions.

It will be recognized by one of skill in the art that the amount of drugrequired for therapeutic effect on administration will, of course, varywith the agent chosen, the nature and severity of the condition and theanimal undergoing treatment, and is ultimately at the discretion of thephysician. Furthermore, the optimal quantity and spacing of individualdosages of a drug will be determined by the nature and extent of thecondition being treated, the form, route and site of administration, theparticular patient being treated and that such optima can be determinedby conventional techniques. It will also be appreciated that the optimalcourse of treatment, this is, the number of doses given, can beascertained by those skilled in the art using conventional course oftreatment determination tests.

As indicated, the preferred highly water-soluble drug will be metforminor a salt thereof, which will be employed in a dosage range from about 2to about 43 mg/kg, preferably about 3 to about 36 mg/kg and morepreferably from about 4.5 to about 30 mg/kg (or from about 150 to about3000 mg, preferably from about 250 to about 2500 mg) on a regimen insingle daily dose or 2 to 4 divided daily doses, 1 to 4 times daily.

Where metformin is to be administered once daily, metformin will beemployed in an amount of at least one gram, preferably from about one toabout 3 grams and more preferably from about 1 to about 2.5 grams, inone, two or more tablets and/or one, two or more capsules.

The biphasic controlled release formulation of the invention may beprepared in accordance with the following method of the invention.

A mixture of medicament (preferably metformin HCl) and hydrophilicpolymer and/or hydrophobic polymer and/or other hydrophobic material aredispersed/dissolved in a suitable solvent such as water or an inertorganic solvent such as ethanol, isopropanol, acetone or dichloromethaneor appropriate mixtures of two or more thereof, to produce asubstantially uniform granulation. The granulation is dried and passedthrough a 0.5 to 2 mm aperture screen to break down agglomerates.

The resulting dry granules are blended with hydrophilic polymer and/orhydrophobic polymer and/or other hydrophobic material. The resulting mixusually with lubricant is pressed into tablets or filled into capsules.

The finished dosage form is either a compressed tablet or a hard gelatincapsule, preferably a tablet. The tablet may be optionally film coated.The total amount of drug per dosage unit would be such as to offer adosage form of convenient size for patients, but following ingestionwould remain (or swell to, by hydration of the polymers used in thefabrication of the tablet) a size that does not easily pass through thepylorus (15 mm or greater) when taken with a meal. As the tablet swellsup to approximately three times its dry size following hydration, drugloads of up to 750 mg and more are possible, dependent upon the actualcharacteristics of the individual drug. Gradual erosion of the polymersof the formulation over a period of up to 15 hours ensures that thedosage form does not produce a gastrointestinal obstruction.

Useful metformin formulations of the invention show the following drugrelease characteristic when tested in vitro.

Time (hours) % released 1 28-39 2 43-57 3 53-70 5 70-88 7 80-98 10 >85

In addition, in accordance with the present invention, the controlledrelease metformin formulation of the invention (relative to therapid-release marketed Glucophage® tablets) reduces maximum attainedplasma-metformin concentration (Cmax) by at least about 15% (preferablyfrom about 15 to about 30%), and increases time to reach maximummetformin plasma concentration (Tmax) by at least about 30% (preferablyfrom about 30 to about 100%), while having an insignificant effect onarea under the plasma-metformin concentration time curve (AUC) and %urinary recovery (UR) of the dose of metformin. Thus, thecontrolled-release metformin formulation of the invention can beemployed for once daily dosing of metformin in the treatment ofdiabetes.

The following Examples represent preferred embodiments of the invention.

EXAMPLE 1 Biphasic Metformin HCl Formulation

25 g of ethylcellulose N10 NF was dissolved/dispersed in 100 ml of 95%ethanol. This dispersion was gradually added to 500 g of metforminhydrochloride in a planetary mixer to produce a uniform dampgranulation. The granulation was dried at 55° C. for one hour and passedthrough a 0.8 mm aperture screen to break down agglomerates. Themetformin-ethylcellulose granules (541 g) were blended with 351.5 g ofhydroxypropylmethylcellulose 2208 USP (100,000 cps grade), 10 g ofhydroxypropylmethylcellulose 2910 USP (5 cps grade) and 100.5 g ofmicrocrystalline cellulose in a planetary mixer for 10 minutes. Finallythis mix was lubricated with 1% w/w magnesium stearate and compressedinto capsule shaped tablets, each containing 500 mg metforminhydrochloride. When subjected to in vitro drug release testing, thefollowing results were obtained.

Time (hours) % metformin released 1 38.1 2 56.3 3 69.5 4 79.7 5 87.4 693.1 7 97.7 8 100

EXAMPLE 2 Biphasic Metformin HCl Formulation

51 g of sodium carboxymethylcellulose (Blanose 7HF) was mixed with 500 gof metformin hydrochloride and granulated with 95% ethanol in a smallplanetary mixer. The damp granulation was passed through a 2 mm aperturescreen and then dried in an oven at 55° C. for one hour. The driedgranulation (530 g) was blended with 344 g ofhydroxypropylmethylcellulose 2208 USP (100,000 cps grade), 9.5 g ofhydroxypropylmethylcellulose 2910 USP (5 cps grade) and 100 g ofmicrocrystalline cellulose in a planetary mixer for 10 minutes. Thisblend was lubricated with 1% w/w magnesium stearate and compressed intocapsule shaped tablets, each containing 500 mg metformin hydrochloride.When the tablets were subjected to in vitro release testing thefollowing results were obtained.

Time (hours) % metformin released 1 35.3 2 51.4 3 62.6 4 70.7 5 76.7 682.1 7 85.3 8 88.5 10 92.6

EXAMPLE 3 Biphasic Metformin HCl Formulation

Metformin hydrochloride (502.5 g) was mixed with sodiumcarboxymethylcellulose (Blanose 7HF) (50 g) for five minutes in a smallplanetary mixer and sufficient purified water added with continuedmixing to produce a damp granular mass. The wet granulation was dried at60° C. for 1 hour and then size reduced in a hammer mill. Thegranulation was dry blended with a mixture prepared from 358 g ofhydroxypropylmethylcellulose 2208 USP (100,000 cps grade), 10 g ofhydroxypropylmethylcellulose 2910 USP (5 cps grade) and 102 g ofmicrocrystalline cellulose in a planetary mixer for 10 minutes. Finallythis mix was lubricated by mixing with 1% w/w magnesium stearate andcompressed into capsule shaped tablets, each containing 0.5 g ofmetformin hydrochloride. When tested for in vitro release of metforminthe following results were obtained.

Time (hours) % metformin released 1 33.1 2 47.6 3 57.5 4 65.1 6 76.5 884.3 10 88.6

EXAMPLE 4 Biphasic Metformin HCl Formulation

200 g of glycerol monostearate was heated to 70° C. in a high shearmixer bowl and 199 g of metformin hydrochloride was added and the mixeroperated with impeller at 90 rpm and chopper at 215 rpm for 5 minutes. Afurther 796 g of metformin hydrochloride was added gradually withcontinued mixing, maintaining thee granulation at 70° C. and with anincrease in chopper speed first to 500 rpm for 13 minutes, then to 1000rpm for a further 3 minutes. The bowl was then cooled to 60° C., theimpeller speed was reduced to 20 rpm and the chopper speed increased to2000 rpm. Cooling was continued with adjustment in impeller and chopperspeed to eventually provide a cooled solid granulation. The cooledgranulation was deagglomerated by passing through a 0.8 mm screen.

540.5 g of the granulation was blended with 350 g ofhydroxypropylmethylcellulose 2208 USP (100,000 cps grade), 10 ghydroxypropylmethylcellulose 2910 USP (5 cps grade) and 100 g ofmicrocrystalline cellulose in a planetary mixer for 10 minutes. Theblend was lubricated by blending with 1% w/w magnesium stearate and thencompressed into capsule shaped tablets each containing 500 mg metforminhydrochloride. When tested for in vitro release of metformin, thefollowing results were obtained.

Time (hours) % metformin released 1 32.4 2 45.7 3 55.8 4 63.7 5 70.3 675.7 8 83.3 10 88.6

EXAMPLE 5 Biphasic Metformin HCl Formulation

Tablets containing 500 mg metformin hydrochloride prepared according toExample 3 or Glucophage brand (or rapid release) metformin hydrochloride500 mg tablets was dosed (2×500 mg tablets) to 24 patients immediatelyafter dinner. Blood samples were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, 7,8, 10, 12, 14, 16, 20, 24 hours and analyzed for metformin. The meanplasma profile demonstrated useful modification of drug release in vivorelative to the immediate release formulation and with no impact onbioavailability in contrast to other metformin extended releaseformulations reported in the literature.

Interpatient variability in pharmacokinetic parameters was acceptable asillustrated by the mean parameters (%CV) given in the table below:

% UR Cmax AUC (inf) (Urinary Formulation (ng/ml) (ng.hr/ml) Tmax*(hr)Recovery) Glucophage 1226(16) 10128(14) 3.5(1,5) 43.3(20) Example 3 978(13) 10483(21)   5(4,8) 42.7(18) *median (min., max.)

For the Example 3 once a day tablet formulation of the invention(relative to the rapid release Gilucophage® tablet), the time requiredto reach maximum metformin plasma concentration (Tmax) is increased byan average of about 40%, and the maximum attained plasma metforminconcentration (Cmax) is reduced by an average of about 20%, yet the areaunder plasma-metformin concentration time curve (AUC) and the % urinaryrecovery (UR) of the dose of metformin are not significantly differentfrom that found with rapid-release Glucophage®. This means that overallpatient exposure to metformin (in both the Example 3 formulation and theGlucophage®) is equivalent.

Thus, in view of the above results, it is seen that the pharmacokineticparameters found for the Example 3 tablet formulation of the inventionindicate that the Example 3 tablet formulation can be employed for oncedaily dosing of metformin in the treatment of diabetes.

The new formulations of the invention thus represent a significantadvance in the once-a-day administration of metformin hydrochloride tohumans in the treatment of diabetes.

EXAMPLE 6 Preparation of Metformin (2:1) Fumarate

Metformin base (8.71 moles) (prepared from the hydrochloride salt via anion-exchange column) was dissolved in methanol/H₂O [5:1]. With stirring,a solution of fumaric acid (4.05 moles) in ethanol was added over aperiod of one hour under a nitrogen atmosphere at ambient temperature(˜20° C.). Crystallization began to occur immediately. After stirringthe slurry for one hour at ambient temperature, the product was filteredoff, washed with ethanol and dried under vacuum to afford the metformin(2:1) fumarate salt as a free-flowing white crystalline solid in 72 M%yield and melting point of 247-249° C.

The resulting metformin (2:1) fumarate slat had a solubility in water(mg/ml) of 140, a hygroscopicity measured at 95% relative humidity/25°C. of less than 7% moisture uptake at 6 hours, and a low compactionsusceptibility.

The so-formed metformin salt is used to prepare a biphasic controlledrelease formulation employing the procedure of Example 3.

EXAMPLE 7 Preparation of Metformin (2:1) Succinate

Metformin base (8.95 moles) (prepared from the hydrochloride salt via anion-exchange column) was dissolved in methanol/H₂O [5:1]. With stirring,a solution of succinic acid (4.42 moles) in ethanol was added over onehour under a nitrogen atmosphere at ambient temperature (˜20°).Crystallization of the salt commenced shortly after addition of thesuccinic acid solution. After stirring the slurry for an hour at ambienttemperature, the product was filtered off, washed with ethanol and driedunder vacuum to form the metformin (2:1) succinate salt as a freeflowing white crystalline solid in 89 M% yield and melting point of246-247° C.

The resulting metformin (2:1) succinate salt had a solubility in water(mg/ml) of 95, a hygroscopicity measured at 95% relative humidity/25° C.of less than 1% moisture uptake at 30 minutes, and a low compactionsusceptibility.

The so-formed metformin salt is used to prepare a biphasic controlledrelease formulation employing the procedure of Example 3.

The metformin formulations described in the aforesaid Examples may beadministered once daily as described above, in one, two or more tabletsand/or capsules to provide optimal therapeutic control.

REFERENCES

1. Vidon, N., Chaussade, S., Noel, M., Franchisseur, C., Huchet, B.,Bernier, J. J. (1988), Diabetes Research and Clinical Practice, 4,223-239.

2. Pentikainen, P. J. (1986), International Journal of ClinicalPharmacology, Therapy and Toxicology, 24, 213-220.

2A. Noel, D. S. (1980), Kinetic study of normal and sustained releasedosage forms of metformin in normal subjects, Journal of InternationalBiomedical Information and Data, 1980, pp. 9 to 20.

2B. Karttunen et al (1983), The pharmacokinetics of metformin: acomparison of the properties of a rapid-release and a sustained-releasepreparation, Int. J. Clin. Pharmacology, Therapy and Toxicology, Vol.21, No. 1, pp. 31-36.

3. Watanabe, S., Kayano, M., Ishino, Y., Miyao, K. (1976), U.S. Pat. No.3,976,764.

4. Sheth, P., Tossounian, J. L. (1979), U.S. Pat. No. 4,140,755.

5. Sheth, P., Tossounian, J. L. (1978), U.S. Pat. No. 4,126,672.

6. Sheth, P., Tossounian, J. L. (1979), U.S. Pat. No. 4,167,558.

7. Dennis, A. B., Lee, K., Timmins, P. (1992), U.S. Pat. No. 5,169,638.

8. Franz, M. R., Oth, M. P. (1993), U.S. Pat. No. 5,232,704.

9. Ishikawa, M., Miyaka, Y., Watanabe, S. (1989), U.S. Pat. No.4,844,905.

10. Davis, S. S., Stockwell, A. F., Taylor, J. J., Hardy, J. G.,Whalley, D. R., Wilson, C. G., Bechgaard, H., Christensen, F. N. (1986)Pharm. Res., 3, 208-213.

11. Timmermans, J., Moes, A. (1994), J. Pharm. Sci., 83, 18-24.

12. Caldwell, L. J., Gardener, C. R., Cargill, R. C. (1988), U.S. Pat.No. 4,767,627.

13. Urquart, J., Theeuwes, F. (1984), U.S. Pat. No. 4,434,153.

14. Shell, J. W. (1990), U.S. Pat. No. 5,007,790.

15. Shell, J. W. (1993), World Patent WO 9318755.

16. Shell, J. W. (1996), U.S. Pat. No. 5,582,837.

17. Fisher, M. C., Morella, A. M. (1994), European Patent 609961.

18. Hansraj, B. R., Bashir, R. H. (1992), European Patent 502642.

19. Rollet, M. (1987), French Patent 2594693.

20. Howard, S. A., Kotwal, P. M. (1997) U. S. Pat. No. 5,645,858.

21. Macrae, R. J., Smith J. S. (1997), World Patent WO 9718814.

22. Belenduik, G. W., McCarty, J. A., Rudnic, E. M. (1996), U.S. Pat.No. 5,484,608.

23. Bhatti, G. K., Edgren, D. E., Hatamkhani, Z., Wong, P. S., Wong, P.S. L. (1994), World Patent WO 9427589.

24. Palepu, N. R., Venkatesh, G. M., (1997) European Patent 701436.

What is claimed is:
 1. A method for treating diabetes comprisingadministering once daily to a mammalian patient in need of treatment atherapeutically effective amount of a pharmaceutical formulationcomprising (1) an inner solid particulate phase, and (2) an outer solidcontinuous phase in which particles of said inner solid particulatephase are dispersed and embedded, the particles of said inner solidparticulate phase comprising (a) a pharmaceutical having a high watersolubility selected from metformin or a pharmaceutically acceptable saltthereof; and (b) an extended release material, and said outer solidcontinuous phase comprising an extended release material, wherein thetotal extended release material content in both said inner solidparticulate phase and said outer continuous phase is within the rangefrom about 25 to about 75% by weight of the pharmaceutical formulation.2. The method for treating diabetes as defined in claim 1 wherein saidpharmaceutical formulation is a biphasic heterogeneous controlledrelease formulation which is designed to release pharmaceutical from theparticles forming said inner solid particulate phase through said outersolid continuous phase into the upper gastrointestinal tract.
 3. Themethod for treating diabetes as defined in claim 1 wherein the totalextended release material content in both said inner solid particulatephase and said outer solid continuous phase is within the range fromabout 30 to about 65% by weight of the pharmaceutical formulation. 4.The method for treating diabetes as defined in claim 1 wherein saidpharmaceutical is metformin hydrochloride.
 5. The method for treatingdiabetes as defined in claim 1 wherein said extended release materialpresent in said inner solid particulate phase is different from theextended release material present in said outer solid continuous phase.6. The method for treating diabetes as defined in claim 1 wherein thetotal extended release material content in both said inner solidparticulate phase and said outer solid continuous phase is within therange from about 35 to about 60% by weight of the pharmaceuticalformulation.
 7. The method for treating diabetes as defined in claim 3wherein said inner solid particulate phase contains from about 5 toabout 95% extended release material based on the weight of said innersolid particulate phase, and the outer solid continuous phase containsfrom about 40 to about 100% extended release material based on theweight of said outer solid continuous phase.
 8. The method for treatingdiabetes as defined in claim 1 wherein said formulation when ingested bya human reduces maximum attained plasma-metformin concentration (Cmax)by at least about 15% (relative to marketed rapid-release metforminformulations), and increases time to reach maximum metformin-plasmaconcentration (Tmax) by at least about 30% (relative to marketedrapid-release metformin formulations), while having an insignificanteffect on area under the plasma-metformin concentration time curve (AUC)and % urinary recovery (UR) of the dose of metformin (relative tomarketed rapid-release metformin formulations).
 9. The method fortreating diabetes as defined in claim 1 wherein said formulationcontains metformin in a therapeutically effective amount which allows apatient a dosing regimen of at least one gram metformin, or apharmaceutically acceptable salt thereof, once daily, while providingeffective control of plasma glucose.
 10. The method for treatingdiabetes as defined in claim 9 wherein said formulation provides for adosing regimen of from about 1 to about 3 grams once daily.
 11. Themethod for treating diabetes as defined in claim 9 wherein said innersolid particulate phase is in the form of discrete individual particlesor granules and said outer solid continuous phase is a substantiallycontinuous matrix having individual particles forming said inner solidparticulate phase embedded therein and dispersed throughout.
 12. Themethod for treating diabetes as defined in claim 9 wherein saidformulation when ingested by a human reduces maximum attainedplasma-metformin concentration (Cmax) by at least about 15% (relative tomarketed rapid-release metformin formulations), and increases time toreach maximum metformin-plasma concentration (Tmax) by at least about30% (relative to marketed rapid-release metformin formulations), whilehaving an insignificant effect on area under the plasma-metforminconcentration time curve (AUC) and % urinary recovery (UR) of the doseof metformin (relative to marketed rapid-release metforminformulations).
 13. The method for treating diabetes as defined in claim1 wherein said metformin is metformin (2:1) fumarate.
 14. The method oftreating diabetes as defined in claim 1 wherein said inner solidparticulate phase of said formulation is present in a weight ratio tosaid outer solid continuous phase within the range from about 0.5:1 toabout 4:1.
 15. The method of treating diabetes as defined in claim 1wherein said pharmaceutical is present in said inner solid particulatephase of said formulation in an amount within the range from about 10 toabout 98% weight of said inner solid particulate phase.
 16. The methodfor treating diabetes as defined in claim 1 wherein said extendedrelease material present in said inner solid particulate phase of saidformulation comprises one or more hydrophilic polymers, and/or one ormore hydrophobic polymers and/or one or more other hydrophobicmaterials; and said extended release material in said outer solidcontinuous phase of said formulation comprises one or more hydrophilicpolymers, and/or one or more hydrophobic polymers and/or one or moreother hydrophobic materials.
 17. The method for treating diabetes asdefined in claim 16 wherein said extended release material present insaid inner solid particulate phase comprises one or more ionic polymersand said extended release material present in said outer solidcontinuous phase comprises one or more non-ionic polymers.
 18. Themethod for treating diabetes as defined in claim 17 wherein said ionicpolymer comprises sodium alginate, carbomer, calciumcarboxymethylcellulose or sodium carboxymethylcellulose, and saidnon-ionic polymer comprises hydroxypropylmethylcellulose 2208 USP,viscosity grade ranging from about 4000 to about 100,000 cps and/orhydroxypropylmethyl cellulose 2910 USP viscosity grade ranging fromabout 3 to about 150 cps.
 19. The method for treating diabetes asdefined in claim 1 wherein said inner solid particulate phase of saidpharmaceutical formulation has a mean particle size within the rangefrom about 30 μm to about 0.8 mm.
 20. The method for treating diabetesas defined in claim 1 wherein said inner solid particulate phase of saidpharmaceutical formulation comprises metformin, metformin hydrochloride,metformin succinate (2:1) salt or metformin fumarate (2:1) salt, andethyl cellulose and/or sodium carboxymethyl cellulose and/orglycerylmonostearate and said outer solid continuous phase compriseshydroxypropylmethylcellulose 2208 USP (100,000 cps), and/orhydroxypropylmethylcellulose 2910 USP (5 cps) and/or microcrystallinecellulose.
 21. The method for treating diabetes as defined in claim 1wherein said pharmaceutical formulation further comprises anotherantihyperglycemic agent and/or hypolipidemic agent.
 22. The method fortreating diabetes as defined in claim 21 wherein said otherantihyperglycemic agent is a sulfonyl urea, a glucosidase inhibitor, athiazolidenedione, insulin, or glucogon-like peptide-1.
 23. The methodfor treating diabetes as defined in claim 21 wherein said otherantihyperglycemic agent is glyburide, glipizide, pioglitazone orrosiglitazone.
 24. The method for treating diabetes as defined in claim21 wherein said hypolipidemic agent is an MTP inhibitor, a squalenesynthetase inhibitor, and HMG CoA reductase inhibitor, a fibric acidderivative, an ACAT inhibitor, a cholesterol absorption inhibitor, anileal Na^(+/)bile cotransporter inhibitor, a bile acid sequestrantand/or nicotinic acid or a derivative thereof.
 25. The method fortreating diabetes as defined in claim 21 wherein said hypolipidelmicagent is pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatinor cerivastatin.
 26. The method for treating diabetes as defined inclaim 21 wherein said metformin is present in a weight ratio to saidother antihyperglycemic agent or hypolipidemic agent within the rangefrom about 0.01:1 to about 300:1.
 27. A method for treating diabetescomprising administering a pharmaceutical formulation comprising (1) aninner solid particulate phase, and (2) an outer solid continuous phasein which particles of said inner solid particulate phase are dispersedand embedded, the particles of said inner solid particulate phasecomprising (a) metformin or a pharmaceutically acceptable salt thereof;and (b) an extended release material, and said outer solid continuousphase comprising an extended release material, wherein said extendedrelease material present in said inner solid particulate phase isdifferent from the extended release material present in said outer solidcontinuous phase and wherein the total extended release material contentin both said inner solid particulate phase and said outer solidcontinuous phase is within the range from about 25 to about 75% byweight of the pharmaceutical formulation.
 28. The method for treatingdiabetes as defined in claim 27 comprising administering saidpharmaceutical formulation which is a biphasic heterogeneous controlledrelease formulation which is designed to release metformin from theparticles forming said inner solid particulate phase through said outersolid continuous phase into the upper gastrointestinal tract.
 29. Themethod for treating diabetes as defined in claim 27 wherein themetformin is metformin hydrochloride.
 30. The method for treatingdiabetes as defined in claim 27 wherein the total extended releasematerial content in both said inner solid particulate phase and saidouter solid continuous phase is within the range from about 30 to about65% by weight of the pharmaceutical formulation.
 31. The method fortreating diabetes as defined in claim 27 wherein said inner solidparticulate phase contains from about 5 to about 95% extended releasematerial based on the weight of said inner solid particulate phase. 32.The method for treating diabetes as defined in claim 27 wherein saidouter solid continuous phase contains from about 40 to about 100%extended release material based on the weight of said outer solidcontinuous phase.
 33. The method for treating diabetes as defined inclaim 27 wherein said inner solid particulate phase is in the form ofdiscrete individual particles or granules and said outer solidcontinuous phase is a substantially continuous matrix having individualparticles forming said inner solid particulate phase embedded thereinand dispersed throughout.
 34. The method for treating diabetes asdefined in claim 27 wherein said metformin is metformin (2:1) fumarate.35. The method of treating diabetes as defined in claim 27 wherein saidinner solid particulate phase is present in a weight ratio to said outersolid continuous phase within the range from about 0.5:1, to about 4:1.36. The method of treating diabetes as defined in claim 27 wherein saidmetformin is present in said inner solid particulate phase in an amountwithin the range from about 10 to about 98% by weight of the inner solidparticulate phase.
 37. The method of treating diabetes as defined inclaim 27 wherein the extended release material present in said innersolid particulate phase comprises one or more hydrophilic polymers,and/or one or more hydrophobic polymers and/or one or more otherhydrophobic materials; and the extended release material in said outersolid continuous phase comprises one or more hydrophilic polymers,and/or one or more hydrophobic polymers and/or one or more otherhydrophobic materials.
 38. The method of treating diabetes as defined inclaim 37 wherein the extended release material present in the innersolid particulate phase comprises one or more ionic polymers and theextended release material present in said outer solid continuous phasecomprises one or more non-ionic polymers.
 39. The method of treatingdiabetes as defined in claim 38 wherein said ionic polymer comprisessodium alginate, carbomer, calcium carboxymethylcellulose or sodiumcarboxymethylcellulose, and said non-ionic polymer compriseshydroxypropylmethylcellulose 2208 USP, viscosity grade ranging fromabout 4000 to about 100,000 cps and/or hydroxypropylmethyl cellulose2910 USP viscosity grade ranging from about 3 to about 150 cps.
 40. Themethod of treating diabetes as defined in claim 27 wherein said innersolid particulate phase has a mean particle size within the range fromabout 30 mm to about 0.8 mm.
 41. The method of treating diabetes asdefined in claim 27 wherein said inner solid particulate phase comprisesmetformin, metformin hydrochloride metformin succinate (2:1) salt ormetformin fumarate (2:1) salt, and ethyl cellulose and/or sodiumcarboxymethyl cellulose and/or glycerylmonostearate and said outer solidcontinuous phase comprises hydroxypropylmethylcellulose 2208 USP(100,000 cps), and/or hydroxypropylmethylcellulose 2910 USP (5 cps)and/or microcrystalline cellulose.
 42. The method of treating diabetesas defined in claim 27 wherein said pharmaceutical formulation furthercomprises another antihyperglycemic agent and/or a hypolipidemic agent.43. The method of treating diabetes as defined in claim 42 wherein saidother antihyperglycemic agent is a sulfonyl urea, a glucosidaseinhibitor, a thiazolidenedione, insulin, or glucogon-like peptide-1. 44.The method of treating diabetes as defined in claim 42 wherein the otherantihyperglycemic agent is glyburide, glipizide, pioglitazone orrosiglitazone.
 45. The method of treating diabetes as defined in claim42 wherein said hypolipidemic agent is an MTP inhibitor, a squalenesynthetase inhibitor, an HMG CoA reductase inhibitor, a fibric acidderivative, an ACAT inhibitor, a cholesterol absorption inhibitor, anileal Na^(+/)bile cotransporter inhibitor, a bile acid sequestrantand/or nicotinic acid or a derivative thereof.
 46. The method oftreating diabetes as defined in claim 42 wherein said hypolipidemicagent is pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatinor cerivastatin.
 47. The method of treating diabetes as defined in claim27 wherein said formulation when ingested by a human reduces maximumattained plasma-metformin concentration (Cmax) by at least about 15%(relative to marketed rapid-release metformin formulations), andincreases time to reach maximum metformin-plasma concentration (Tmax) byat least about 30% (relative to marketed rapid-release metforminformulations), while having an insignificant effect on area under theplasma-metformin concentration time curve (AUC) and % urinary recovery(UR) of the dose of metformin (relative to marketed rapid-releasemetformin formulations).
 48. A method of lowering insulin resistancewhich comprises administering once daily to a mammalian patient in needof such treatment a therapeutically effective amount of a pharmaceuticalformulation comprising (1) an inner solid particulate phase, and (2) anouter solid continuous phase in which particles of said inner solidparticulate phase are dispersed and embedded, the particles of saidinner solid particulate phase comprising (a) a pharmaceutical having ahigh water solubility selected from metformin or a pharmaceuticallyacceptable salt thereof; and (b) an extended release material, and saidouter solid continuous phase comprising an extended release material,wherein the total extended release material content in both said innersolid particulate phase and said outer continuous phase is within therange from about 25 to about 75% by weight of the pharmaceuticalformulation.
 49. The method of lowering insulin resistance as defined inclaim 48 wherein the total extended release material content in bothsaid inner solid particulate phase and said outer solid continuous phaseis within the range from about 30 to about 65% by weight of thepharmaceutical formulation.
 50. The method of lowering insulinresistance as defined in claim 48 wherein the total extended releasematerial content in both said inner solid particulate phase and saidouter solid continuous phase is within the range from about 35 to about60% by weight of the pharmaceutical formulation.
 51. The method oflowering insulin resistance as defined in claim 48 wherein saidformulation when ingested by a human reduces maximum attainedplasma-metformin concentration (Cmax) by at least about 15% (relative tomarketed rapid-release metformin formulations), and increases time toreach maximum metformin-plasma concentration (Tmax) by at least about30% (relative to marketed rapid-release metformin formulations), whilehaving an insignificant effect on area under the plasma-metforminconcentration time curve (AUC) and % urinary recovery (UR) of the doseof metformin (relative to marketed rapid-release metforminformulations).
 52. The method of lowering insulin resistance as definedin claim 48 wherein said extended release material present in said innersolid particulate phase comprises one or more hydrophilic polymers,and/or one or more hydrophobic polymers and/or one or more otherhydrophobic materials; and the extended release material in said outersolid continuous phase comprises one or more hydrophilic polymers,and/or one or more hydrophobic polymers and/or one or more otherhydrophobic materials.
 53. The method of lowering insulin resistance asdefined in claim 48 wherein said inner solid particulate phase of saidpharmaceutical formulation comprises metformin, metformin hydrochloride,metformin succinate (2:1) salt or metformin fumarate (2:1) salt, andethyl cellulose and/or sodium carboxymethyl cellulose and/orglycerylmonostearate and said outer solid continuous phase compriseshydroxypropylmethylcellulose 2208 USP (100,000 cps), and/orhydroxypropylmethylcellulose 2910 USP (5 cps) and/or microcrystallinecellulose.
 54. The method of lowering insulin resistance as defined inclaim 48 wherein said pharmaceutical formulation further comprisesanother antihyperglycemic agent and/or hypolipidemic agent.
 55. A methodof lowering insulin resistance which comprises administering to amammalian patient in need of such treatment a therapeutically effectiveamount of a pharmaceutical formulation comprising (1) an inner solidparticulate phase, and (2) an outer solid continuous phase in whichparticles of said inner solid particulate phase are dispersed andembedded, the particles of the inner solid particulate phase comprising(a) metformin or a pharmaceutically acceptable salt thereof; and (b) anextended release material, and said outer solid continuous phasecomprising an extended release material, wherein the extended releasematerial present in said inner solid particulate phase is different fromthe extended release material present in said outer solid continuousphase and wherein the total extended release material content in bothsaid inner solid particulate phase and said outer solid continuous phaseis within the range from about 25 to about 75% by weight of thepharmaceutical formulation.
 56. The method of lowering insulinresistance as defined in claim 55 wherein the total extended releasematerial content in both said inner solid particulate phase and said outsolid continuous phase is within the range from about 30 to about 65% byweight of the pharmaceutical formulation.
 57. The method of loweringinsulin resistance as defined in claim 55 wherein the extended releasematerial present in said inner solid particulate phase comprises one ormore hydrophilic polymers, and/or one or more hydrophobic polymersand/or one or more other hydrophobic materials; and the extended releasematerial in said outer solid continuous phase comprises one or morehydrophilic polymers, and/or one or more hydrophobic polymers and/or oneor more other hydrophobic materials.
 58. The method of lowering insulinresistance as defined in claim 55 wherein said inner solid particulatephase comprises metformin, metformin hydrochloride, metformin succinate(2:1) salt or metformin fumarate (2:1) salt, and ethyl cellulose and/orsodium carboxymethyl cellulose and/or glycerylmonostearate and saidouter solid continuous phase comprises hydroxypropylmethylcellulose 2208USP (100,000 cps), and/or hydroxypropylmethylcellulose 2910 USP (5 cps)and/or microcrystalline cellulose.
 59. The method of lowering insulinresistance as defined in claim 55 wherein said pharmaceuticalformulation further comprises another antihyperglycemic agent and/orhypolipidemic agent.
 60. The method of lowering insulin resistance asdefined in claim 55 wherein said formulation when ingested by a humanreduces maximum attained plasma-metformin concentration (Cmax) by atleast about 15% (relative to marketed rapid-release metforminformulations), and increases time to reach maximum metformin-plasmaconcentration (Tmax) by at least about 30% (relative to marketedrapid-release metformin formulations), while having an insignificanteffect on area under the plasma-metformin concentration time curve (AUC)and % urinary recovery (UR) of the dose of metformin (relative tomarketed rapid-release metformin formulations).